Theralink Technologies Inc (THER)

[zigzagman]

OBMP announced that the European Patent Office has approved the Company's patent application number 12701292.0 protecting ProscaVax as a PSA (prostate specific antigen) cancer vaccine.

The patent is broad in scope covering an array of therapeutic cancer vaccine compositions built upon OncBioMune's protein and antigen platform technology. The patent protects OncBioMune's PSA cancer vaccine in 38 participating European Patent Organisation states.

ProscaVax is a novel protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damage to healthy cells. OncBioMune is preparing to commence a Phase 2 trial in the U.S. evaluating ProscaVax in early-stage prostate cancer patients in the "active surveillance" category. OncBioMune and its Mexican Joint Venture partner Vitel Laboratorios S.A. de C.V. ("Vitel") are sponsoring a Phase 2/3 clinical study of ProscaVax in Mexico evaluating the vaccine as a new treatment for recurrent prostate cancer in hormone-naïve and hormone-independent patients. As previously disclosed, OncBioMune and Vitel are working on finalizing documentation in which OncBioMune will acquire Vitel to pursue development and commercialization of drugs and drug candidates in the U.S., Latin America and worldwide.

"Our patent portfolio is now very robust, including covering ProscaVax in key markets, including the U.S., Mexico and now Europe," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "Protection of intellectual property is integral to our strategy to become a global pharmaceutical brand."

https://finance.yahoo.com/news/oncbiomune-awarded-patent-europe-protecting-142855803.html